Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 511 clinical trials
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

systemic therapy
cancer chemotherapy
  • 28 Oct, 2022
  • 18 locations
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in …

metastatic pancreatic adenocarcinoma
hematologic malignancy
  • 04 Oct, 2022
  • 1 location
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study

This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor …

  • 19 Apr, 2022
  • 1 location
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection

This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that has spread to other places in the body (advanced) and who are undergoing treatment for human immunodeficiency virus (HIV). Cabozantinib may stop the growth of tumor cells by blocking some of the …

antiretroviral therapy
enzyme-linked immunosorbent assay
HIV Vaccine
  • 24 Oct, 2022
  • 1 location
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. …

major surgery
growth factor
kinase inhibitor
programmed cell death 1 ligand 1
  • 27 Oct, 2022
  • 171 locations
Metastatic Tumor Research and Outcomes Network (MTRON)

The registry aims to collect patient information such as patient demographics, co-morbidities, clinical, diagnostic, and therapeutic data, as well as information on adverse events and HRQOL outcomes specific for patients with metastatic spine tumor(s).

  • 30 Jan, 2022
  • 25 locations
Tissue Collection Framework To Improve Outcomes In Solid Tumours

. However, metastatic cancer still develops in a large number of patients and drug resistance occurs in the majority of them after an initial period of response and leads to cancer progression and death

  • 04 Mar, 2022
  • 1 location
A Study in Radiotherapy-related Nervous System Complications

Purpose: This observational study aims to evaluate the clinical manifestations, therapeutic effects, progress and prognosis in radiotherapy-related nervous system complications. OUTLINE: This is an observational clinical trial. Patients are enrolled and administrated with optimized clinical treatment. Blood, urine, stool, cerebrospinal fluid (CSF), imaging and other examinations, and scale assessments are …

  • 25 Jan, 2021
  • 1 location
Patient-derived Organoids Predicts the Clinical Efficiency of Colorectal Liver Metastasis

primary and metastatic tumor in patients with liver metastasis.

  • 25 Mar, 2022
  • 1 location
Measuring Fatty Acid Oxidation in Cerebral Metastases Using [18F]FPIA

Cerebral metastases represent a significant problem for oncological management. It is estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain during the course

  • 26 Mar, 2021
  • 1 location